Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | ALTA-1L: brigatinib vs crizotinib in ALK+ aNSCLC

Stephen Liu • 30 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer Alectinib Brigatinib Crizotinib
ALTA-1L

Stephen Liu, MD, MedStar Georgetown University Hospital, Washington, DC, discusses the ALTA-1L study (NCT02737501) investigating brigatinib versus crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Stephen Liu

1:41
Managing ALK+ NSCLC
Stephen Liu • 30 Jan 2020
1:30
A shifting paradigm: lung cancer
Stephen Liu • 30 Jan 2020
1:48
Stephen Liu: BTOG highlights
Stephen Liu • 30 Jan 2020
5:08
Actionable lung cancer targets
Stephen Liu • 30 Jan 2020

Related Videos

0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
1:56
Challenges and opportunities in TILs and TCR modified cell therapies
Sebastian Klobuch • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals